Stockreport

China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China [Yahoo! Finance]

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atop [Read more]